Researchers at Baylor College of Medicine have discovered that metformin, the most prescribed diabetes drug in the world, lowers blood sugar through a previously unknown pathway in the brain. The breakthrough, published in Science Advances, reveals the drug suppresses a small protein called Rap1 in the ventromedial hypothalamus (VMH), triggering neurons that regulate glucose levels independently of the liver.

The brain responds to metformin at concentrations thousands of times lower than the liver and intestines require. When researchers injected tiny amounts directly into the brains of diabetic mice, blood sugar dropped significantly — even at doses far below what is typically given orally. This explains why the drug works so well at relatively low clinical doses.

The finding opens the door to an entirely new class of diabetes treatments that target the brain pathway directly, potentially with fewer side effects. The team also plans to investigate whether this same Rap1 signaling is behind metformin's other documented benefits, including slowing brain aging and reducing cancer risk.